Envudeucitinib (ESK-001)
Moderate-to-Severe Plaque Psoriasis
Phase 3Active
Key Facts
About Alumis
Alumis is a clinical-stage biotech advancing a late-stage portfolio of precision oral therapies for immune-mediated diseases, leveraging a proprietary data analytics platform to de-risk development. The company's lead asset, envudeucitinib, has delivered strong Phase 3 data in plaque psoriasis, potentially positioning it as a best-in-class oral TYK2 inhibitor. With a seasoned leadership team and a $2.91B valuation, Alumis's strategy focuses on bringing its lead program to market while expanding into adjacent immunology indications to build a multi-product company.
View full company profileTherapeutic Areas
Other Moderate-to-Severe Plaque Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| ICOTYDE (icotrokinra) | Johnson and Johnson Innovative Medicine | Approved |
| TAK-279 (NDI-034858) | Takeda | Phase 3 |
| ILUMYA® (tildrakizumab-asmn) | Sun Pharmaceutical | Commercial |
| Iruxolimab (AK101) | Akeso | Approved |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Approved |
| ORKA-001 | Oruka Therapeutics | Phase 1/2 |